Poolbeg Pharma PLC (AIM:POLB)
London · Delayed Price · Currency is GBP · Price in GBX 3.000
-0.150 (-4.76%)
Jul 17, 2025, 4:35 PM GMT+1
Poolbeg Pharma Company Description
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom.
The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome.
It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses.
Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Poolbeg Pharma PLC
| Country | United Kingdom |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Jeremy Skillington |
Contact Details
Address: 40 Bank Street London, E14 5NR United Kingdom | |
| Phone | 44 20 7183 1499 |
| Website | poolbegpharma.com |
Stock Details
| Ticker Symbol | POLB |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BKPG7Z60 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeremy Skillington | Chief Executive Officer |
| Ian O'Connell | Chief Financial Officer |
| Laura Maher | Chief Operating Officer |
| Carol Dalton | Head of Investor Relations |